Litifilimab (BIIB059)

Timeline

Study Dates

Start Date

June 2021

Est. Completion

December 2026

Enrollment Target

400 participants

Status

Active (not recruiting)

Study Design

Primary Endpoint

Efficacy and safety of litifilimab in adults with active SLE receiving background nonbiologic lupus standard of care

Registry

ClinicalTrials.gov Record

Registry ID

NCT04895241

Direct Link

Related Treatment

Treatment Being Studied